Shannon Schneider

Company: LEO Pharma

Job title: Senior Director - Medical Affairs & Tralokinumab

Seminars:

Panel Discussion: Personalized Medicine’s Place in Dermatology Drug Discovery 11:00 am

How can advancements in molecular profiling and biomarker identification facilitate the implementation of personalized medicine approaches in dermatological drug development? What challenges exist in translating personalized medicine concepts, such as pharmacogenomics and patient stratification, into actionable strategies for dermatology drug discovery? As a more personalized medicine approach narrows addressable patient population size, what do commercial…Read more

day: Day Two Discovery Track AM

Targeting IL-13 With Tralokinumab Normalizes Type 2 Inflammation in Atopic Dermatitis Both Early & at 2 Years 11:15 am

Evaluation of skin and serum biomarkers from patients enrolled in the Phase 3 ECZTRA 1 trial and long-term extension ECZTEND trials with Tralokinumab (IL-13 neutralizing monoclonal antibody) Gene expression assessed by RNA sequencing and protein expression assessed by immunohistochemistry and immunoassay Measuring Tralokinumab treatment’s improvement of epidermal pathology, along with reducing systemic markets of Type…Read more

day: Day One Clinical Track AM